Enliven Therapeutics (ELVN) Assets (2019 - 2026)

Enliven Therapeutics (ELVN) has 8 years of Assets data on file, last reported at $464.9 million in Q1 2026.

• For the quarter ending Q1 2026, Assets rose 53.63% year-over-year to $464.9 million; the trailing twelve-month figure through Mar 2026 stood at $464.9 million (up 53.63% YoY), and the FY2025 full-year result was $476.2 million, up 46.17% from the prior year.
• Assets fell to $464.9 million in Q1 2026, from $476.2 million in the prior quarter.
• In the past five years, Assets ranged from a high of $503.9 million in Q2 2025 to a low of $59.1 million in Q3 2022.
• A 5-year average of $292.1 million and a median of $302.9 million in 2023 frame the typical range for Assets.
• Across the five-year window, Assets plunged 44.78% in 2022 and soared 363.66% in 2023, its largest moves.
• Tracing ELVN's Assets over 5 years: stood at $83.3 million in 2022, then surged by 226.38% to $271.9 million in 2023, then gained by 19.82% to $325.8 million in 2024, then soared by 46.17% to $476.2 million in 2025, then decreased by 2.38% to $464.9 million in 2026.
• Business Quant data shows ELVN's Assets at $464.9 million in Q1 2026, $476.2 million in Q4 2025, and $490.9 million in Q3 2025.